A method of detection of DNA end(s) in a biological material, comprising the steps: i. preparation of the biological material, wherein the preparation of the biological material comprises fixation, or providing fixed biological material; ii. modification of DNA end(s) by chemical or physical processing followed by binding of molecules [molecules type 1] to the DNA end(s) by catalytic or noncatalytic means, wherein the molecules bound to the DNA end(s) [molecules type 1] serve as a target for binding of antibodies or fragments thereof [molecules type 2 / 3] ; iii. addition of two different antibodies or fragments thereof [molecules type 2 / 3] that bind to the molecules bound to the DNA end(s) [molecules type 1] and which are linked to oligonucleotides [oligonucleotides type 1] , wherein the two antibodies [molecules type 2 / 3] recognise different binding sites in the molecules bound to the DNA end(s) [molecules type 1] ; iv. addition of two different oligonucleotides [oligonucleotides type 2] that hybridise with the linked oligonucleotides [oligonucleotides type 1], and enzyme ligase to create ligatable ends of the oligonucleotides [oligonucleotides type 2] that are hybridized with the linked oligonucleotides [oligonucleotides type 1] , wherein the ligatable ends are ligated to form a circular oligonucleotide hybridised to the linked oligonucleotides [oligonucleotides type 1] , wherein the circular oligonucleotide comprises the two different oligonucleotides [oligonucleotides type 2] ; v. performing rolling circle amplification; and vi. detection of amplification products to detect the DNA end(s), wherein the detection of the amplification products comprises detection of labelled oligonucleotides [oligonucleotides type 3] that hybridise with the amplification products. i. preparation of the biological material, wherein the preparation of the biological material comprises fixation, or providing fixed biological material; ii. modification of DNA end(s) by chemical or physical processing followed by binding of molecules [molecules type 1] to the DNA end(s) by catalytic or noncatalytic means, wherein the molecules bound to the DNA end(s) [molecules type 1] serve as a target for binding of antibodies or fragments thereof [molecules type 2 / 3] ; iii. addition of two different antibodies or fragments thereof [molecules type 2 / 3] that bind to the molecules bound to the DNA end(s) [molecules type 1] and which are linked to oligonucleotides [oligonucleotides type 1] , wherein the two antibodies [molecules type 2 / 3] recognise different binding sites in the molecules bound to the DNA end(s) [molecules type 1] ; iv. addition of two different oligonucleotides [oligonucleotides type 2] that hybridise with the linked oligonucleotides [oligonucleotides type 1], and enzyme ligase to create ligatable ends of the oligonucleotides [oligonucleotides type 2] that are hybridized with the linked oligonucleotides [oligonucleotides type 1] , wherein the ligatable ends are ligated to form a circular oligonucleotide hybridised to the linked oligonucleotides [oligonucleotides type 1] , wherein the circular oligonucleotide comprises the two different oligonucleotides [oligonucleotides type 2] ; v. performing rolling circle amplification; and vi. detection of amplification products to detect the DNA end(s), wherein the detection of the amplification products comprises detection of labelled oligonucleotides [oligonucleotides type 3] that hybridise with the amplification products. <EOS>